此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

SHR-2173 在系统性红斑狼疮患者中的研究

2026年9月24日 更新者:Guangdong Hengrui Pharmaceutical Co., Ltd

一项多中心、随机、双盲、安慰剂对照的II期临床研究,旨在评估SHR-2173注射液在系统性红斑狼疮患者中的疗效和安全性

This study is a randomized, double-blind, multi-center, placebo-controlled Phase II clinical trial to evaluate the efficacy and safety of SHR-2173 in adult participants with active Systemic Lupus Erythematosus (SLE), including a 4-week screening period, a 24-week core treatment period, a 24-week maintenance treatment period, and a 12-week safety follow-up period. Approximately 245 SLE patients will be included.

研究概览

研究类型

介入性

注册 (估计的)

248

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Beijing Municipality
      • Beijing、Beijing Municipality、中国、100005
        • 招聘中
        • Chinese Academy of Medical Sciences, Peking Union Medical College Hospital
        • 首席研究员:
          • Xiaofeng Zeng
        • 接触:
    • Shanghai Municipality
      • Shanghai、Shanghai Municipality、中国、200127
        • 招聘中
        • Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
        • 首席研究员:
          • Liangjing Lv
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 65年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Male and female participants aged 18 through 65 years (including boundary value)at the time of screening.
  2. The Body Mass Index (BMI) ≥18 kg/m ² at the time of screening.
  3. Diagnosed with SLE for at least 6 months prior to screening.
  4. ANA≥1:80, or anti-dsDNA antibodies and/or anti-Sm antibodies above the upper limit of the normal range as determined by a central laboratory at the time of screening.
  5. High disease activity at screening and at baseline.
  6. Currently receiving at least one or more of the following standard therapies for SLE at stable doses: oral corticosteroids (OCS), antimalarial drugs, and conventional immunosuppressants.
  7. Participants thoroughly understand the content, process and possible adverse reactions before the trial, and voluntarily sign the written informed Consent Form (ICF).
  8. Female subjects with fertility or male participants whose partners are women of childbearing age must avoid donating sperm/eggs from the date of signing the ICF until 12 weeks after the last study medication, and agree to take contraceptive measures as specified in the protocol.

Exclusion Criteria:

  1. The presence of any of the following medical histories or comorbidities: a) Severe lupus-related kidney disease and/or kidney damage; b) Active neuropsychiatric SLE occurred 6 months prior to screening; c) Autoimmune, inflammatory or joint diseases other than SLE and LN that may interfere with the interpretation of the test results or clinical assessment, including but not limited to rheumatoid arthritis, overlap syndrome, psoriasis/psoriatic arthritis, eczema, inflammatory bowel disease, and any other vasculitis; d) There was catastrophic or severe antiphospholipid syndrome within 12 months prior to screening; e) Have a history of progressive multifocal leukoencephalopathy (PML); f) Have a history of organ transplantation.
  2. Use any of the following medications /treatments or participate in a clinical trial: a) Previously received gene therapy such as CAR-T or T-cell Engager (TCE) ; b) Received anti-CD20 monoclonal antibody within 6 months and other B-cell or plasma cell depletion treatments within 6 to 12 months prior to randomization; c) Received biologic therapy targeting BAFF, APRIL or interferon receptor within 12 weeks prior to randomization; d) Received Alkylating agents within 12 weeks prior to randomization; e) Received any other biological agents for the treatment of SLE within 12 weeks prior to randomization; f) Received inhibitors of Janus kinase (JAK), Bruton tyrosine kinase (BTK), or tyrosine kinase 2 (TYK2) within 12 weeks prior to randomization; g) Received intra-articular, intramuscular or intravenous corticosteroid for SLE within 4 weeks prior to randomization; h) Received a live/attenuated live vaccine within 4 weeks prior to randomization or planned to receive it during the trial period.
  3. The presence of the following tumor risks or accompanied by other poorly controlled serious or chronic diseases: a) Suffering from malignant tumors or having a history of malignant tumors; b) Accompanying other poorly controlled serious or chronic diseases during or at the time of screening, including but not limited to endocrine diseases, cardiovascular diseases, neurological/mental disorders, kidney diseases, severe digestive system diseases, severe respiratory system diseases, neurological diseases, and other serious liver, gallbladder, metabolic or lymphatic system diseases, etc.
  4. Infection-related medical history and examinations: a) Herpes zoster infection meets one of the following conditions: 1) A history of systemic herpes zoster, such as disseminated herpes zoster, herpetic encephalitis or ocular herpes zoster involving the retina; 2) Recurrent herpes zoster that has occurred twice or more within two years; 3) The herpes zoster infection has not completely subsided within 12 weeks before screening; b) Tuberculosis (TB) or occult tuberculosis infection; c) A history of primary immunodeficiency, splenectomy, and any potential conditions that make participants susceptible to infection; d) A history of repeated infections requiring hospitalization and intravenous antibiotics; e) Hospitalization and/or intravenous anti-infective treatment were required within 8 weeks prior to randomization, or any infection that required oral anti-infective treatment within 2 weeks prior to randomization; f) Positive test results for any of the following: hepatitis B surface antigen (HBsAg), hepatitis C virus antibody, Treponema pallidum antibody or human immunodeficiency virus (HIV); If the test result is negative for HBsAg but positive for hepatitis B core antibody (HBcAb), regardless of whether the hepatitis B surface antibody (HBsAb) is positive or negative, HBV-DNA testing is required to determine the situation: if HBV-DNA is positive, participants should be excluded. Participants can be included if HBV-DNA is negative.
  5. General situation: a) Pregnant or lactating women; b) Having a history of alcohol abuse or illegal drug abuse within one year prior to screening; c) Individuals with allergic constitutions, or those known to be intolerant or allergic to any component of the investigational drug; d) Participants who have undergone major surgeries within the 3 months prior to screening, or those who plan to undergo major surgeries during the trial period; e) Investigators determine that there are circumstances that affect the safety and efficacy evaluation of the investigational drug, or other circumstances not appropriate for participation in this study.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:SHR-2173注射组

SHR-2173 injection in different doses.

安慰剂比较:SHR-2173 注射剂安慰剂组

SHR-2173 injection placebo.

研究衡量的是什么?

主要结果指标

结果测量
大体时间
第24周达到系统性红斑狼疮应答指数-4(SRI-4)的参与者比例。
大体时间:在第24周。
在第24周。

次要结果测量

结果测量
大体时间
达到SRI-4指标的参与者比例。
大体时间:最长至第48周。
最长至第48周。
达到基于英国爱尔兰狼疮评估组(BILAG)的综合狼疮评估(BICLA)的参与者比例。
大体时间:截至第48周。
截至第48周。
基线 SLE 疾病活动指数 2000 (SLEDAI-2K) 评分降低 ≥ 4 分的参与者比例。
大体时间:直至第48周。
直至第48周。
方案中低剂量皮质类固醇治疗下达到SRI-4标准的参与者比例。
大体时间:最长至第48周。
最长至第48周。
每日泼尼松(或等效药物)剂量≤7.5 mg的参与者比例(仅限于基线皮质类固醇剂量>7.5 mg/天的患者)。
大体时间:至第48周。
至第48周。
患者总体评估(PGA)相对于基线的变化。
大体时间:长达第 48 周。
长达第 48 周。
在方案中达到狼疮低疾病活动状态(LLDAS)的参与者比例。
大体时间:长达48周。
长达48周。
达到方案中系统性红斑狼疮缓解定义(DORIS)标准的受试者比例。
大体时间:最长至第48周。
最长至第48周。
抗dsDNA抗体水平较基线的变化。
大体时间:截至第48周。
截至第48周。
补体(C3、C4)水平相对于基线的变化。
大体时间:截至第48周。
截至第48周。
相对于基线的CD19+B细胞水平变化。
大体时间:至第48周。
至第48周。
方案中慢性病治疗疲劳功能评估(FACIT-F)相对于基线的变化。
大体时间:截至第 48 周。
截至第 48 周。
方案中系统性红斑狼疮特异性生活质量量表(SLEQOL)相对于基线的变化。
大体时间:截至第48周。
截至第48周。
Adverse events, vital signs, physical examinations, laboratory tests, 12-lead electrocardiograms, etc.
大体时间:The entire process of the trial , about two years.
The entire process of the trial , about two years.

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年4月3日

初级完成 (估计的)

2028年3月1日

研究完成 (估计的)

2028年11月1日

研究注册日期

首次提交

2025年11月28日

首先提交符合 QC 标准的

2025年12月9日

首次发布 (实际的)

2025年12月23日

研究记录更新

最后更新发布 (实际的)

2026年9月29日

上次提交的符合 QC 标准的更新

2026年9月24日

最后验证

2026年5月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅